

DAFTAR PUSTAKA

- Acharya, L.D., Rau, N.R., Udupa, N., Rajan, M.S., dan Vijayanarayana, K., 2016, Assessment of cost of illness for diabetic patients in South Indian tertiary care hospital, *Journal of Pharmacy & Bioallied Sciences*, 8 (4): 314–320.
- Adam , R. D., Victor, M., dan Ropper, A. H., 2005, *Principles of Neurology*, McGraw-Hill, NewYork.
- Ambianti, N., Andayani, T. M., dan Sulistiawaty, E., 2019, Analisis Biaya Penyakit Diabetes Melitus Sebagai Pertimbangan Perencanaan Pembiayaan Kesehatan, *Jurnal Farmasi Galenika*, 5(1): 73-83.
- American Diabetes Association, 2017, *American Diabetes Association : Standards of Medical Care in Diabetes-2017*, the American Diabetes Association, USA.
- American Diabetes Association, 2018, Economic Costs of Diabetes in the U.S. in 2017, *Diabetes care*, 41(5), 917–928, <https://doi.org/10.2337/dci18-0007>.
- American Diabetes Association, 2022, Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers, *Clin Diabetes*, 40(1) : 10–38, <https://doi.org/10.2337/cd22-as01>.
- Andayani, T. M., dkk., 2010, Assessing The Impact Of Complications On The Direct Medical Costs Of Type 2 Diabetes Mellitus Outpatients, *International Journal of Current Pharmaceutical Research*.
- Asita, I. N., 2018, Analisis Biaya dan Faktor yang mempengaruhi Besarnya Biaya Terapi pada Penderita Diabetes Melitus Tipe 2 Rawat Jalan di RSUD kota Yogyakarta, Skripsi, Fakultas Farmasi Universitas Gadjah Mada Yogyakarta.
- Bahia, L. R., dkk., 2011, The Costs of Type 2 Diabetes Mellitus Outpatient Care in The Brazilian Public Health System, *Value in Health : The Journal of The International Society for Pharmacoeconomics and Outcomes Research*, 14(5 Suppl 1), S137–S140.
- BPJS Kesehatan, 2021, *Penyakit Katastropik Berbiaya Mahal Tetap Dijamin Program JKN-KIS*, Edisi 104, Media Info BPJS Kesehatan, Jakarta.
- CDC, 2013, *Adult Diabetes Prevalence in New York State*, Centers for Disease Control and Prevention Department of Health.
- Cryer, P. E., 2013, Mechanisms of Hypoglycemia-Associated Autonomic Failure in Diabetes, *N Engl J Med.*, 369:362–72.

- D'adamo, P., 2008, *Diet Sehat Diabetes Sesuai Golongan Darah*, Delapratasa, Yogyakarta.
- Damayanti, S., 2015, *Diabetes Melitus dan Penatalaksanaan Keperawatan*, Nuha Medika, Yogyakarta.
- Dinas Kesehatan Yogyakarta, 2020, *Profil Kesehatan Kota Yogyakarta Tahun 2020 (Data Tahun 2019)*, Diunduh dari Dinas Kesehatan Yogyakarta : <https://kesehatan.jogjakota.go.id/>.
- DiPiro, J. T., Wells, B. G., Schwinghammer, T. L., dan DiPiro, C. V., 2015, *Pharmacotherapy Handbook 9th Edition*, McGraw-Hill Education, New York.
- Djamhari, E. A., dkk., 2020, *Defisit Jaminan Kesehatan Nasional (JKN): Mengapa dan Bagaimana Mengatasinya?*, Perkumpulan PRAKARSA, Jakarta.
- Ezeani, dkk., 2020, Prevalence and Risk Factors for Diabetes Mellitus in a State in South East Nigeria: Result of a Population Based House to House Survey, *Current Diabetes Reviews*, 16(2): 181-187, <https://doi.org/10.2174/1573399815666190619142708>.
- Fitri, E., Andayani, T. M., dan Suparniati, E., 2015, Cost Analysis of Diabetes Mellitus, *Jurnal Manajemen dan Pelayanan Farmasi*, 5(1).
- Ganesan, K., Rana, M. B. M., dan Sultan, S., 2022, *Oral Hypoglycemic Medications*, StatPearls Publishing, Diunduh dari NCBI : <https://www.ncbi.nlm.nih.gov/books/NBK482386/>.
- Geer, E. B. dan Shen, W., 2009, Gender Differences in Insulin Resistance, Body Composition, and Energy Balance, *Gender Medicine*, 6 Suppl 1(Suppl 1), 60–75, <https://doi.org/10.1016/j.genm.2009.02.002>.
- Henriksson, F., dkk., 2000, Direct Medical Cost Patients with Type 2 Diabetes in Sweden, *Journal of Internal Medicine*, 248: 387-396.
- International Diabetes Federation, 2021, *IDF Diabetes Atlas 10th Edition*, Diunduh dari IDF Diabetes Atlas : <https://diabetesatlas.org/>.
- Jaldin-Fincati J. R., dkk., 2017, Update on GLUT4 Vesicle Traffic: A Cornerstone of Insulin Action, *Trends in Endocrinology and Metabolism*.
- Janigan, R., 2018, Diabetic Retinopathy, *Ferri's Advisor 2018*, 392-392.e3.
- Javanbakht, M., Baradaran, H.R., Mashayekhi, A., Haghdooost, A.A., Khamseh, M.E., Kharazmi, E. dkk., 2011, Cost of Illness Analysis of Type 2 Diabetes Melitus In Iran, *PLOS ONE*, 6, 1–7.

- Juster-Switlyk, K., dan Smith, A. G., 2016, Updates in diabetic peripheral neuropathy, *F1000Research*, 5, 1–7, <https://doi.org/10.12688/f1000research.7898>.
- Kementrian Kesehatan Republik Indonesia, 2013^a, *Buku Pegangan Sosialisasi Jaminan Kesehatan Nasional (JKN) dalam Sistem Jaminan Sosial Nasional*, Kementrian Kesehatan RI, Jakarta.
- Kementrian Kesehatan Republik Indonesia, 2013^b, *Pedoman Penerapan Kajian Farmakoekonomi*, Kementrian Kesehatan RI, Jakarta.
- Kementrian Kesehatan Republik Indonesia, 2016^a, *Peraturan Menteri Kesehatan Republik Indonesia No. 52 tahun 2016 tentang Standar Tarif Pelayanan Kesehatan dalam Penyelenggaraan Program Jaminan kesehatan*, Kementrian Kesehatan RI, Jakarta.
- Kementrian Kesehatan Republik Indonesia, 2016^b, *Peraturan Menteri Kesehatan Republik Indonesia No. 76 tahun 2016 tentang Pedoman Indonesian Case Base Groups (INA-CBG) Dalam Pelaksanaan Jaminan Kesehatan Nasional*, Kementrian Kesehatan RI, Jakarta.
- Kementrian Kesehatan Republik Indonesia, 2020, *Tetap Produktif Cegah dan Atasi Diabetes Melitus*, Pusat Data dan Informasi Kementrian Kesehatan RI, Jakarta.
- Kim, K. S., Lee, B. W., Kim, Y. J., Lee, D. H., Cha, B. S., dan Park, C. Y., 2019, Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment, *Diabetes Metab J.*, 43:127–143.
- Kim, D. D., dkk., 2020, Perspective and Costing in Cost-Effectiveness Analysis, *PharmacoEconomics*, 38(10), 1135–1145, <https://doi.org/10.1007/s40273-020-00942-2>.
- Koster, I., dkk., 2006, The Cost Burden of Diabetes Mellitus: The Evidence from German – The CoDIM Study, *Article Diabetologi*, 49: 1498-1504.
- Kuate-Tegueu, C., Temfack, E., Ngankou, S., Doumbe, J., Dijentcheu, V. P., & Kengne, A. P., 2015, Prevalence and determinants of diabetic polyneuropathy in a sub-Saharan African referral hospital, *Journal of the Neurological Science*, 355(1), 108–112, <https://doi.org/10.1016/j.jns.2015.05.035>.
- Lathifah, N. L., 2017, Hubungan Durasi Penyakit dan Kadar Gula Darah dengan Keluhan Subyektif Penderita Diabetes Melitus, *Jurnal Berkala Epidemiologi*, 5(2) : 231-239.

- Lemeshow, S., Hosmer Jr, D.W., Klar, J., Lwanga, S.K., 1990, *Adequacy of Sample Size in Health Studies*, 1-2, John & Sons Ltd, England.
- Logue, J., Walker, J. J., Colhoun, H. M., Leese, G. P., Lindsay, R. S., McKnight, J. A., Morris, A. D., Pearson, D. W., Petrie, J. R., Philip, S., Wild, S. H., Sattar, N., dan Scottish Diabetes Research Network Epidemiology Group, 2011, Do men develop type 2 diabetes at lower body mass indices than women?, *Diabetologia*, 54(12), 3003–3006, <https://doi.org/10.1007/s00125-011-2313-3>.
- Marwaningtyaz, A. S., 2018, Analisis Biaya Terapi pada Pasien Diabetes Melitus Tipe 2 Rawat Jalan di RSUD Sleman D.I Yogyakarta, Skripsi, Fakultas Farmasi Universitas Gadjah Mada Yogyakarta.
- Maskari, F., El-Sadig, M., dan Nagelkerke, N., 2010, Assessment of the Direct Medical Cost's of Diabetes Mellitus and its Complications in the United Arab Emirates, *Biomed Central. Ltd*, 10, 679.
- Meier, J. J., 2012, GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus, *Nat Rev Endocrinol*, 8:728–42.
- Murphy, E. M., Rodis, J. L., dan Mann, H. J., 2020, Three Ways to Advocate for The Economic Value of The Pharmacist in Health Care, *J Am Pharm Assoc* (2003), 60(6):e116–e124.
- Mursalin dan Soewondo, P., 2016, Analisis Estimasi Biaya Langsung Medis Penderita Rawat Jalan Diabetes Mellitus Tipe 2 di RSUD Dr. Abdul Aziz Singkawang Tahun 2013, *Jurnal Ekonomi Kesehatan Indonesia*, 1 (2).
- Nadjib, M., Putri, S., Sabarinah, dan Trihandini, I., 2020, *Evaluasi Ekonomi di Bidang Kesehatan : Teori dan Aplikasi*, Universitas Indonesia Publishing, Jakarta.
- Oktadiana, I., 2021, Perbandingan Biaya Riil Pada Pasien Diabetes Mellitus Tipe 2 Dengan Tarif INA-CBG'S di Rumag Sakit Umum Daerah, *Jurnal Farmasi Tinctura*, 2, 47.
- PERKENI, 2021, *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, PB PERKENI, Jakarta.
- Posner, B. I., 2017, Insulin Signalling: The Inside Story, *Canadian Journal of Diabetes*.
- Pratiwi, A. E. dan Sukmawati, H., 2019, Analisis Biaya Rata-Rata Pasien Rawat Inap dengan Penyakit Diabetes Mellitus Type II (Studi di Jembrana dan Gianyar), *Jurnal Lingkungan dan Pembangunan*, 3(2) : 21-29.

- Purnamasari, D., 2009, *Diagnosis dan Klasifikasi Diabetes Mellitus*, In: Sudoyo, Aru W., Bambang Setyohadi, Idrus Alwi, Marcellus Simadibrata, Siti Setiati, Buku Ajar Ilmu Penyakit Dalam Jilid III Ed 5, Interna Publishing, Jakarta.
- Putri, E. K., Darmawan, E., dan Perwitasari, D. A., 2019, Cost of Illness Type 2 Diabetes Melitus Tipe 2 dan Komplikasinya pada Peserta Jaminan Kesehatan Nasional (JKN) di Rawat Jalan Ruah Sakit Condong Catur Yogyakarta, *Jurnal Farmasi Indonesia*, 16(2) : 89-101.
- Rena, G., Hardie, D. G., dan Pearson, E. R., 2017, The Mechanisms of Action of Metformin, *Diabetologia*, 60:1577–1585.
- Rochmah, W., 2007, *Buku Ajar Ilmu Penyakit Dalam: Diabetes Mellitus pada Usia Lanjut*, Pusat Penerbitan IPD FKUI, Jakarta.
- Roshanov, P. S. dan Dennis, B. B., 2015, Incretin-based Therapies are Associated with Acute Pancreatitis: Meta-analysis of Large Randomized Controlled Trials, *Diabetes Res Clin Pract*, 110:e13–17.
- Sanchez-Rangel, E. dan Inzucchi, S. E., 2017, Metformin: Clinical Use in Type 2 Diabetes, *Diabetologia*, 60:1586–1593.
- Sesti, G, dkk., 2019, Ten Years of Experience with DPP-4 Inhibitors for The Treatment of Type 2 Diabetes Mellitus, *Acta Diabetol*.
- Shrestha, S. S., dkk., 2018, Economic Costs Attributable to Diabetes in Each US State, *Diabetes Care*, 41:2526–2534.
- Struijs, J.N., Baan, C.A., Schellevis, F.G., Westert, G.P., Bos, G.A.M.V.D., 2006, Comorbidity in Patients with Diabetes Mellitus : Impact on Medical Health Care Utilization, *BMC Health Services Research*, 1-9.
- Suastika, K., Dwipayana, P., Semadi, M.S., dan Kuswardhani, R.A.T., 2012, *Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases*, InTech.
- Suhadi, R., 2020, *Seluk Beluk Hipertensi Peningkatan Kompetensi Klinis untuk Pelayanan Kefarmasian*, Sanata Dharma University Press, Yogyakarta.
- Tahrani, A. A., Barnett, A. H., dan Bailey, C. J., 2016, Pharmacology and Therapeutic Implications of Current Drugs for Type 2 Diabetes Mellitus, *Nat Rev Endocrinol*, 12:566–592.
- Thomas, M. C. dan Cherney, D. Z. I., 2018, The Actions of SGLT2 Inhibitors on Metabolism, Renal Function and Blood Pressure, *Diabetologia*, 61:2098–2107.

- Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., dan Fernandez-Llimos, F., 2021, Principles of Pharmacoeconomic Analysis: The Case of Pharmacist-led Interventions, *Pharmacy Practice*, 19(1):2302.
- Tran, L., dkk., 2015, Pharmacologic Treatment of Type 2 Diabetes: Oral Medications, *Ann Pharmacother*, 49:540–556.
- Wang, W., dkk., 2010, Factors Affecting Costs and Utilization of Type 2 Diabetes Healthcare: A Cross-Sectional Survey Among 15 Hospitals in Urban China, *BMC Health Services Research*, 10:24.
- Widiyani, R., 2013, *Cegah DM Perkecil Biaya Kesehatan Hingga 30 Persen*, International Pharmaceutical Manufacturers Group, Jakarta.
- Wild, S., Roglic, G., Green, A., Sicree, R., dan King, H., 2004, Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030, *NCBI*, 5 : 47-53.
- World Health Organization, 2016, *ICD-10 International Statistical Classification of Diseases and Related Health Problems*, World Health Organization, France.
- Yuniarti, E., Amalia, dan Handayani, T. M., 2015, Analisis Biaya Terapi Penyakit Diabetes Melitus Pasien Jaminan Kesehatan Nasional di RS PKU Muhammadiyah Yogyakarta-Perbandingan Terhadap Tarif INA CBGS, *Jurnal Kebijakan Kesehatan Indonesia*, 4, 103.
- Zahtamal, Chandra, F., Suyanto, dan Restuastuti, T., 2007, Faktor-Faktor Resiko Pasien Diabetes Melitus, *Berita Kedokteran Masyarakat*, 23:142–147.
- Zimmet, P., 2009, Preventing Diabetic Complication: A Primary Care Prospective, *Diabetes Res Clin Pract*, 84:107.